# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: James Madison (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN007-SYN-TD
- Date: 1774-06-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Josiah Pembroke-Achebe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week review after the diagnosis of functional/dissociative seizures. **S**

## History of present illness

Mr. Madison returns six weeks after the diagnosis. He finished the levetiracetam taper three weeks ago; his events have not increased, and the irritability has gone. He has had four psychotherapy sessions and keeps his event diary: three events in six weeks, each shorter than before, all at the end of long study days or after poor sleep. He has begun to notice a warning feeling of distance and heaviness, and once stopped an event by grounding himself. He understands and accepts the diagnosis, and has explained it to two friends. His mood is still low most mornings and he worries a great deal about his examinations; he would like help beyond the therapy. He has had no thoughts of death or self-harm, and the rifle remains locked. He has not driven. **S**

| Element | Detail |
|---|---|
| Events | Three in six weeks, shorter; one stopped by grounding |
| Levetiracetam | Stopped three weeks ago; no rebound; irritability gone |
| Psychotherapy | Four sessions |
| PHQ-9 and GAD-7 | 11 and 12 |
| Safety | No suicidal thoughts; rifle locked; not driving |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight 54.6 kg; no fever |
| Neurological | Positive | Three typical events; no new kinds of event, injury, or tongue biting |
| Psychiatric | Positive | Low mood in the mornings and much worry; sleep about six and a half hours; no suicidal thoughts |

3 systems reviewed. **S**

## Current medications

- Sertraline 50 mg oral tablet, half a tablet (25 mg) each morning for one week, then one tablet (50 mg) each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 112/70 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 54.6 kg; BMI 19.3 kg/m². All vital signs are synthetic.

PHQ-9: 11; GAD-7: 12. All results are synthetic.

## Change since baseline

- PHQ-9: 13 at baseline, 11 at this visit **S**
- GAD-7: 14 at baseline, 12 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Better kept; engaged |
| Mental status | Mood "heavy in the mornings"; affect reactive; logical; no suicidal ideation; insight good |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Functional/dissociative seizures** (F44.5). Fewer and shorter events after four sessions, and he is learning to recognize and interrupt them; no rebound after stopping levetiracetam, which confirms that it was not needed. **S**
   - Continue the twelve psychotherapy sessions and the diary.
   - Still not driving; the three-month event-free interval has not started.
2. **Taking an antiseizure medicine without a confirmed diagnosis** (Z79.899). Resolved: levetiracetam stopped three weeks ago. **S**
   - No antiseizure medicine; a note on his record and emergency card asks that typical events not be treated with benzodiazepines or antiseizure medicines.
3. **Major depressive disorder, single episode, moderate** (F32.1). PHQ-9 11, little changed from 13 at intake despite psychotherapy; item 9 scored 0. Shared decision to add an SSRI, which helps depression and anxiety; in the LaFrance trial sertraline alone did not reduce events, so psychotherapy remains the main treatment for the seizures. **S**
   - Sertraline 25 mg each morning for one week, then 50 mg.
   - Nurse telephone check in two weeks for side effects and safety.
   - Safety plan reviewed; 988 Suicide & Crisis Lifeline confirmed.
4. **Generalized anxiety disorder** (F41.1). GAD-7 12, down from 14. **S**
   - Sertraline as above; worry and examination anxiety addressed in therapy.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 11, down from 13 at intake; item 9 scored 0 |
| Survey | GAD-7 | With the PHQ-9 when anxiety accompanies depression | Completed today | 12, down from 14 |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior; rifle locked; protective factors unchanged |
| Examination | Event diary: frequency, duration, triggers, warning sensations, and injuries | Every visit | Completed today | Three events in six weeks, shorter, linked to long study days and poor sleep; one interrupted by grounding; no injuries |
| Medication safety | Antiseizure medicine review | At diagnosis and until withdrawn | Completed today | Taper completed three weeks ago with no rebound in events |
| Medication safety | SSRI tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Due | Sertraline starts today; nurse telephone check booked for two weeks |
| Referral | CBT-informed psychotherapy for functional seizures | Weekly during the course | Completed today | Four of twelve sessions attended |
| Self-management | Driving | Every visit until cleared | Completed today | Not driving |
| Self-management | Sleep, studies, and first-aid plan | Every visit | Completed today | Sleeping about six and a half hours; agreed to stop studying by 10 pm; testing accommodations requested |
| Laboratory | Lithium, anticonvulsant mood-stabilizer, or antipsychotic monitoring | Only on those drugs | Not indicated | Not taking any; no bipolar features |

## Goal progress

- Cause of the episodes established by the second visit. Outcome by 1774-04-30: Functional/dissociative seizures documented by video-EEG; epilepsy and syncope excluded. **S**
- Antiseizure medicine stopped safely. Outcome by 1774-06-11: Levetiracetam tapered over three weeks and stopped, with no change in events and less irritability. **S**
- Events reduced by at least half, then free of events for three months. In progress; target 1774-12-31. **S**
- Depression and anxiety improved by at least 50 percent (PHQ-9 and GAD-7). In progress; target 1774-12-31. **S**
- No suicidal thoughts. In progress; target 1774-12-31. **S**

## Medication changes

- Started: Sertraline 50 mg oral tablet, half a tablet (25 mg) each morning for one week, then one tablet (50 mg) each morning **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- Hingray C, et al. Functional/dissociative seizures: Proposal for a new diagnostic label and definition by the ILAE task force. Epilepsia 2025;66(11):4162-4182 (PMID 40884444) (2025), International League Against Epilepsy
- LaFrance WC Jr, et al. Multicenter pilot treatment trial for psychogenic nonepileptic seizures: a randomized clinical trial. JAMA Psychiatry 2014;71(9):997-1005 (PMID 24989152) (2014), JAMA Psychiatry
- Goldstein LH, et al. Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial. Lancet Psychiatry 2020;7(6):491-505 (PMID 32445688) (2020), Lancet Psychiatry
- Tolchin B, et al. Seizures, Driver Licensure, and Medical Reporting Update: An AAN Position Statement. Neurology 2025;104(7):e213459 (PMID 40073306) (2025), American Academy of Neurology, American Epilepsy Society, and Epilepsy Foundation of America
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense

## Follow-up

- Nurse telephone check in two weeks; preventive visit next month; three-month review. **S**
- Next scheduled visit 1774-07-16: preventive health visit at 23. **S**
